Variables | Univariate analysis | Multivariate analysis | ||||
HR | 95% CI of HR | P value | HR | 95% CI of HR | P value | |
GSE30219 | ||||||
TILSig (high/low) | 1.981 | 1.491 to 2.633 | <0.001 | 1.584 | 1.184 to 2.118 | 0.002 |
Age | 1.038 | 1.024 to 1.053 | <0.001 | 1.037 | 1.022 to 1.052 | <0.001 |
Gender (male/female) | 1.701 | 1.082 to 2.674 | 0.022 | 1.398 | 0.886 to 2.206 | 0.150 |
Stage (III/IV vs I/II) | 3.036 | 2.234 to 4.127 | <0.001 | 2.810 | 2.059 to 3.835 | <0.001 |
GSE31210 | ||||||
TILSig (high/low) | 2.422 | 1.219 to 4.812 | 0.012 | 2.322 | 1.147 to 4.703 | 0.019 |
Age | 1.025 | 0.978 to 1.075 | 0.306 | 1.035 | 0.988 to 1.085 | 0.147 |
Gender (male/female) | 1.519 | 0.780 to 2.955 | 0.219 | 1.100 | 0.549 to 2.201 | 0.789 |
Stage (II /I) | 4.232 | 2.175 to 8.236 | <0.001 | 4.290 | 2.164 to 8.502 | <0.001 |
TCGA | ||||||
TILSig (high/low) | 1.305 | 1.028 to 1.656 | 0.028 | 1.338 | 1.054 to 1.698 | 0.017 |
Age | 1.017 | 1.003 to 1.030 | 0.014 | 1.020 | 1.006 to 1.034 | 0.004 |
Gender (male/female) | 0.995 | 0.780 to 1.270 | 0.970 | 0.966 | 0.756 to 1.234 | 0.782 |
Stage (III/IV vs I/II) | 1.901 | 1.476 to 2.45 | <0.001 | 2.008 | 1.555 to 2.592 | <0.001 |
TCGA, The Cancer Genome Atlas; TILSig, tumor-infiltrating immune-related lncRNA signature.